Liquid biopsy accurately told whether a lung cancer patient had a mutation that makes the disease treatable with certain pills that can have remarkable effects.The test could also tell if less-fortunate patients had a different mutation, saving them weeks or months of treatment that would ultimately be useless. The findings published in JAMA Oncology revealed the following things.
Plasma ddPCR detected EGFR and KRAS mutations rapidly with the high specificity needed to select therapy and avoid repeat biopsies. It may also detect EGFR T790M missed by tissue genotyping due to tumor heterogeneity in resistant disease.
The study investigated the sensitivity, specificity, test turnaround time, and robustness of droplet digital polymerase chain reaction–based plasma genotyping for the rapid detection of targetable genomic alterations in patients with advanced non–small-cell lung cancer.
Read the complete article here
We are in Playstore
Download the app Here
The study investigated the sensitivity, specificity, test turnaround time, and robustness of droplet digital polymerase chain reaction–based plasma genotyping for the rapid detection of targetable genomic alterations in patients with advanced non–small-cell lung cancer.
Read the complete article here
We are in Playstore
Download the app Here